Kinetic Technologies Announces New IEEE® 802.3bt-Compliant Powered Device and DC-DC Flyback Controller Solution for PoE Power Supplies
15.11.2022 09:00:00 EET | Business Wire | Press release
Power management and video/audio interface IC leader Kinetic Technologies announced today the KTA1140 IEEE 802.3bt-compliant Powered Device Interface IC and the KTB1095 synchronous flyback control IC with integrated digital isolated feedback as the latest additions to their PoE and DC-DC Converter product lines.
Fully compliant with IEEE 802.3bt, 802.3at and 802.3af standards, the KTA1140 integrates input surge protection, a PD controller with 100V, low resistance 0.1Ω hot-swap MOSFET, which fully supports input power levels up to 90W. The PD controller also includes eight-event classification, ATDET, PD Detect, over temperature protection and under voltage lockout (UVLO). The KTA1140 is also designed to provide seamless support for local supplies down to 9.5V.
The KTB1095 is a highly integrated synchronous flyback converter with internal feedback utilizing a 3000VRMS digital isolator, designed to eliminate the need for an external opto-coupler, reducing cost and size. Operating over a wide operating voltage range from 5V to 100V, the KTB1095 includes both primary and secondary side, high current MOSFET drivers and employs current-mode constant on-time control for fast transient response. Featuring an adjustable soft-start function to limit start-up in-rush current, the KTB1095 also includes input voltage UVLO, output over-voltage-protection (OVP), cycle-by-cycle current limit, short-circuit protection and thermal shutdown.
“Our goal at Kinetic is to make it as easy as possible for our customers to design their power supplies,” said Erik Ogren, Kinetic Technologies’ Senior Director of Marketing. “The KTA1140 supports Class 8, 90W designs with its ultra-low resistance hot-swap MOSFET and simplifies system designs with local voltage support. KTB1095 takes advantage of Kinetic’s Tru-Iso™ technology to deliver integrated 3000V-rms on-chip digital isolator feedback, reducing BOM count and PCB area.”
KTA1140 and KTB1095 are sampling now, with production expected to begin in the first quarter of 2023.
Visit Kinetic Technologies for further information.
Key Product Highlights:
KTA1140 – PoE 802.3bt PD Interface
-
Fully supports IEEE® 802.3bt
- Input Power Levels Up to 90W
- Class 0-8 for PoE PD
- Compatible with IEEE® 802.3af/at
- IEC 61000-4-2/3/4/5/6 requirements for EMC
- Seamless support for local power down to 9.5V
- Programmable DC current limit
- Low resistance (typ. 0.1Ω) Hot Swap MOSFET
- 5x5 mm, 20 lead QFN Package
KTB1095 – 100V Synchronous Flyback Controller with Digital Isolation
- Wide 5V to 100V Operating Voltage Range
-
Integrated Digital Isolator Feedback
- 3000V-rms Integrated Isolation
- ±1% Voltage Reference
-
Integrated primary and secondary side MOSFET Drivers
- 3A Sink / 2A Source driving capability
- Adjustable Switching Frequency from 100kHz to 700kHz
- Integrated Protection: Cycle-by-cycle current limit, Input UVLO, OCP, SCP, TSP
- SOIC-16 Wide Body (10.3mm x 7.5mm) Package
About Kinetic Technologies
Kinetic Technologies is a global designer, developer, and provider of proprietary and innovative high-performance analog and mixed-signal semiconductor products for a wide variety of markets. Kinetic’s products help its customers efficiently regulate power, intelligently protect their devices from harmful voltage and current spikes, and deliver high-bandwidth, low-latency, and secured connectivity for video, display, and general-purpose applications.
For more information, please visit http://www.kinet-ic.com/.
*Kinetic Technologies’ logo is a trademark of Kinetic Technologies. All other brand and product names appearing in this document are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005531/en/
Contact information
Robert Bendz
Phone: +1 -408-746-9000
Email: rbendz@kinet-ic.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom